Prominence of Oxidative Stress in the Management of Anti-tuberculosis Drugs Related Hepatotoxicity

Advanced medical services and treatments are available for treating Tuberculosis. Related prevalence has increased in recent times. Unfortunately, the continuous consumption of related drugs is also known for inducing hepatotoxicity which is a critical condition and cannot be overlooked. The present review article has focused on the pathways causing these toxicities and also the role of enzyme CYP2E1, hepatic glutathione, Nrf2-ARE signaling pathway, and Membrane Permeability Transition as possible targets which may help in preventing the hepatotoxicity induced by the drugs used in the treatment of tuberculosis.
Source: Drug Metabolism Letters - Category: Drugs & Pharmacology Source Type: research

Related Links:

Authors: Multani PK, Modi R, Basu S Abstract PURPOSE: To investigate recurrence patterns following anti-tubercular therapy (ATT) in different anatomical presentations of ocular tuberculosis (OTB). METHODS: Retrospective analysis of clinically diagnosed OTB patients divided anatomically into groups A (anterior + intermediate uveitis) and B (posterior + panuveitis). Recurrence was defined as reappearance of intraocular inflammation in a quiescent eye following completion of at least 6-months ATT. Anatomical sites of recurrence were compared to that of presentation. RESULTS: No significant difference in post-A...
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research
CONCLUSION: Definite diagnosis of unilateral choroidal effusion was done. A comprehensive workup is needed to exclude potential malignant process. PMID: 32644830 [PubMed - as supplied by publisher]
Source: Ocular Immunology and Inflammation - Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research
More research emerged this week in potential support of using the tuberculosis vaccine Bacillus Calmette-Guerin (BCG) as a tool in the fight against coronavirus.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
CONCLUSIONS: This is the ninth case of tuberculosis infection under immunotherapy and it underlines the need to consider infection risks in patients undergoing immunotherapy. An INF-γ release assay screening test should be considered an essential part of the pre-treatment work-up. PMID: 32636051 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Publication date: Available online 10 July 2020Source: Saudi Journal of Biological SciencesAuthor(s): Ali Sami Dehyab, Mohd Fadzelly Abu Bakar, Mohamed Khalid AlOmar, Siti Fatimah Sabran
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Publication date: Available online 9 July 2020Source: Clinical Epidemiology and Global HealthAuthor(s): Gyan Chandra Kashyap, Santosh Kumar Sharma, Shri Kant Singh
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
Conditions:   HIV/AIDS;   Tuberculosis Intervention:   Behavioral: Choice Architecture Sponsors:   Johns Hopkins University;   University of Witwatersrand, South Africa;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   HIV/AIDS;   Tuberculosis Intervention:   Behavioral: Choice Architecture Sponsors:   Johns Hopkins University;   KNCV Tuberculosis Foundation;   Clinton Health Access Initiative, Zimbabwe;   Aurum Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   HIV/AIDS;   Tuberculosis Intervention:   Behavioral: Choice Architecture Sponsors:   Johns Hopkins University;   University of Witwatersrand, South Africa;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   HIV/AIDS;   Tuberculosis Intervention:   Behavioral: Choice Architecture Sponsors:   Johns Hopkins University;   KNCV Tuberculosis Foundation;   Clinton Health Access Initiative, Zimbabwe;   Aurum Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Drugs & Pharmacology | Toxicology | Tuberculosis